Background:
Some patients with atopic dermatitis (AD) have an inadequate response or intolerance to dupilumab. Stapokibart, a novel anti-IL-4Rα antibody, is a potential alternative.
Objective:
To assess the real-world effectiveness and safety of switching from dupilumab to stapokibart in moderate-to-severe AD.
Methods:
This retrospective study included 85 patients (67 mild and 18 moderate-to-severe after dupilumab) who switched to stapokibart for ≥16 weeks. Efficacy and safety were evaluated over 16 weeks.
Results:
Stapokibart led to rapid and significant improvements in all patients. By week 16, the Eczema Area and Severity Index (EASI) scores dramatically decreased, and high rates of EASI-90 (89.6% mild and 88.9% moderate-to-severe) were achieved. The mild group showed faster and deeper remission (e.g., EASI-100: 71.6% vs 50.0%). Disease control and quality of life improved significantly. The most common adverse event (AE) was injection site reaction (2.4%); no serious AEs or discontinuations occurred.
Conclusion:
Switching to stapokibart is an effective and safe strategy for patients with an inadequate response to dupilumab, inducing rapid and profound clinical improvement. It is a valuable sequential treatment for AD.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
